US FDA: Magellan Failed To Ensure Lead Test Accuracy
Executive Summary
A US FDA Form-483 inspection report form shows GMP, complaint handling and Medical Device Reporting violations at the Massachusetts facility of Magellan, which is facing serious scrutiny over lead test mishaps.
You may also be interested in...
Magellen Gets Warning Letter On Lead Test Concerns
The warning letter alleges the company sold modified versions of its blood lead tests without alerting US FDA, and didn’t tell the agency about reported discrepancies in test results. FDA first warned of possible faulty test results in May.
US FDA: BD Didn't Document Faulty Lead-Test Warning
An FDA-483 released as part of an ongoing probe into Magellen’s faulty LeadCare tests found potential GMP and Medical Device Reporting violations at a BD location.
US FDA, CDC Warn Of False Results On Lead Blood Tests
Common blood tests for lead poisoning manufactured by Magellan Diagnostics could give false low results if used with venous blood, FDA warned. About 8 million of the tests have been performed since 2014.